Invesco Ltd. Has $132.38 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Invesco Ltd. increased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 308.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,975,241 shares of the biotechnology company’s stock after purchasing an additional 3,001,204 shares during the quarter. Invesco Ltd.’s holdings in Exelixis were worth $132,376,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Principal Securities Inc. lifted its holdings in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 373 shares in the last quarter. USA Financial Formulas acquired a new stake in Exelixis in the 4th quarter valued at approximately $32,000. Kestra Investment Management LLC bought a new stake in Exelixis in the 4th quarter valued at approximately $39,000. UMB Bank n.a. boosted its position in Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 553 shares during the last quarter. Finally, Crowley Wealth Management Inc. acquired a new position in Exelixis during the 4th quarter worth approximately $50,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently commented on EXEL shares. Stifel Nicolaus boosted their price objective on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. Citigroup boosted their price target on shares of Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. JMP Securities restated a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Brookline Capital Management initiated coverage on Exelixis in a report on Monday, December 23rd. They set a “buy” rating on the stock. Finally, Barclays increased their price target on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Price Performance

Shares of EXEL opened at $35.31 on Friday. The company’s 50-day moving average is $36.16 and its 200-day moving average is $33.95. The firm has a market capitalization of $9.88 billion, a PE ratio of 19.95, a PEG ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.